Bavarian Nordic Announces Expansion of IMVAMUNE® Orders from Canadian Government
(Thomson Reuters ONE) -
COPENHAGEN, Denmark, October 28, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that the Public Health Agency of Canada (PHAC) has
ordered 143,000 doses of IMVAMUNE(® )(liquid-frozen formulation), a non-
replicating smallpox vaccine. This order, valued at USD 6.4 million, follows the
delivery of IMVAMUNE to the national stockpile earlier this year, and will help
to secure protection for Canadians, including those individuals who are
contraindicated to traditional smallpox vaccines, such as HIV-infected and
people suffering from skin disorders.
This order, which is the result of an option exercise under an existing contract
between Bavarian Nordic and PHAC, is the fourth order of IMVAMUNE by Canadian
authorities over a seven-year period. After this exercise, an option for
additional doses of IMVAMUNE remains under the contract with PHAC. Bavarian
Nordic expects a continuation of the PHAC partnership and foresees additional
contractual exercises in the future.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "The
international expansion of sales of our smallpox vaccine remains a key factor in
the success of the IMVAMUNE franchise. As ours is the only approved smallpox
vaccine in both Canada and the European Union, we continue to view IMVAMUNE as a
major asset to the company. We are proud to increase our deliveries to the
Canadian government and look forward to a successful relationship in the
future."
Starting in 2008, the DND placed an initial order of IMVAMUNE for the Canadian
armed forces and have continued to replace this stockpile upon expiry. After
approval of IMVAMUNE in Canada in 2013, Bavarian Nordic and PHAC entered into a
contract for IMVAMUNE for use in a public health emergency setting in
individuals who are contraindicated to replicating smallpox vaccines.
As the majority of IMVAMUNE doses will be delivered to PHAC in 2016 and the
revenue will be recognized in 2016, no changes are made in the Company's
expectations for its financial results for 2015.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
About IMVAMUNE Smallpox Vaccine
IMVAMUNE is being developed as a smallpox vaccine for individuals for whom
traditional replicating vaccines are contraindicated, such as people with atopic
dermatitis (AD) and HIV. IMVAMUNE is the Company's most advanced commercial
program. Studies comprising more than 7,600 subjects, including people diagnosed
with AD or infected with HIV, demonstrate that IMVAMUNE has a favorable safety
profile. In 2013, the vaccine was approved in Canada under the trade name
IMVAMUNE and in the European Union under the trade name IMVANEX(®).
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities. Additionally, in collaboration with the
National Cancer Institute, Bavarian Nordic has developed a portfolio of active
cancer immunotherapies, including PROSTVAC(®), which is currently in Phase 3
clinical development for the treatment of advanced prostate cancer. The company
has partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
regarding our expectations as to the timing of the exercise by PHAC of its
remaining option to purchase additional doses of IMVAMUNE and the timing of our
deliveries under and recognition of revenues from this current order of
IMVAMUNE, as well as statements concerning our plans, objectives, goals, future
events, performance and/or other information that is not historical information.
All such forward-looking statements are expressly qualified by these cautionary
statements and any other cautionary statements which may accompany the forward-
looking statements. We undertake no obligation to publicly update or revise
forward-looking statements to reflect subsequent events or circumstances after
the date made, except as required by law.
201529en:
http://hugin.info/100065/R/1961917/715475.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1961917]
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2015 - 07:30 Uhr
Sprache: Deutsch
News-ID 429910
Anzahl Zeichen: 6293
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Announces Expansion of IMVAMUNE® Orders from Canadian Government"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
